US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products

Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.  

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
FDA Commissioner Stephen Hahn also said that the agency could issue an emergency use authorization for a vaccine for a patient subgroup if warranted. • Source: Shutterstock

Stephen Hahn is trying to enlist health care providers to build public confidence in the coronavirus vaccine and therapeutics that the US Food and Drug Administration soon could make available.

In a 10 August virtual presentation to the American Medical Association, the FDA commissioner reiterated that the FDA will not cut corners in its decisions on whether to approve a coronavirus vaccine or therapeutic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Vaccines

More from Pink Sheet

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.